Premium
Efficacy of alogliptin, a dipeptidyl peptidase‐4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) – receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes
Author(s) -
Sakata Koji,
Hayakawa Manabu,
Yano Yuichiro,
Tamaki Noboru,
Yokota Naoto,
Eto Takuma,
Watanabe Reiko,
Hirayama Naoteru,
Matsuo Takeshi,
Kuroki Kazuo,
Sagara Seiji,
Mishima Osamu,
Koga Masahiro,
Nagata Naoto,
Nishino Yuri,
Kitamura Kazuo,
Kario Kazuomi,
Takeuchi Masayoshi,
Yamagishi Shoichi
Publication year - 2013
Publication title -
diabetes/metabolism research and reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.307
H-Index - 110
eISSN - 1520-7560
pISSN - 1520-7552
DOI - 10.1002/dmrr.2437
Subject(s) - alogliptin , albuminuria , endocrinology , medicine , glycation , creatinine , type 2 diabetes , advanced glycation end product , diabetes mellitus , urine , dipeptidyl peptidase 4 inhibitor , dipeptidyl peptidase 4 , glycemic , urology
Background To examine the effects of alogliptin, a dipeptidyl peptidase‐4 inhibitor, on glucose parameters, the advanced glycation end product (AGE)‐receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes patients. Methods Sixty‐one patients whose HbA lc ≥ 6.1% (mean age 64.7 years; 67% men; mean HbA lc 7.4%; 57% were pharmacologically treated) underwent blood and urine sampling and analysis before and after 12 weeks of treatment with alogliptin (25 mg once daily). Results Alogliptin treatment significantly reduced fasting glucose (160.3 mg/dL at baseline versus 138.0 mg/dL at 12 weeks), glycoalbumin (21.1% at baseline versus 18.9% at 12 weeks), HbAlc (7.4% at baseline versus 6.9% at 12 weeks), circulating soluble form of RAGE concentrations (847.3 pg/mL at baseline versus 791.4 pg/mL at 12 weeks) and urine albumin to creatinine ratio (31.6 mg/g Cr at baseline versus 26.5 mg/g Cr at 12 weeks), whereas 1,5‐anhydroglucitol concentrations were significantly increased (7.5 µg/mL at baseline versus 11.6 µg/mL at 12 weeks; all P < 0.05). Circulating AGEs concentrations were reduced only in patients with baseline AGEs ≥7 U/mL ( n = 33, from 8.2 U/mL to 7.2U /mL; p < 0.01) after alogliptin treatment. The treatment‐induced change of soluble form of sRAGE concentrations was associated with changes of 1,5‐anhydroglucitol and HbA lc concentrations ( rho = −0.32 and 0.29, respectively). Meanwhile, the treatment‐induced change of urine albumin to creatinine ratio was associated with a change in the fasting glucose concentration ( rho = 0.25; all p < 0.05). During the intervention, alogliptin treatment was well tolerated without any hypoglycemia or side effects. Conclusion Alogliptin treatment improved the AGE–RAGE axis and reduced albuminuria in Japanese type 2 diabetes patients. Copyright © 2013 John Wiley & Sons, Ltd.